ACM
IBRX icon

Aster Capital Management’s ImmunityBio IBRX Stock Holding History

Aster Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-182,089
Closed -$548K – 1038
2026
Q1 		$548K Buy
182,089
+182,057
+568,928% +$1.25M 0.18% 127
2025
Q4 		$63 Buy
+32
New +$72 ﹤0.01% 1049
2025
Q2 		– Sell
-13,463
Closed -$44.3K – 1285
2025
Q1 		$44.3K Buy
13,463
+11,459
+572% +$34.7K 0.01% 847
2024
Q4 		$5.13K Buy
+2,004
New +$8.35K ﹤0.01% 855

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aster Capital Management's IBRX Position: Q2 2026 in Review

Aster Capital Management sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 182,089 shares — an estimated $548K sold.

Aster Capital Management first reported a position in IBRX in Q4 2024 and held it in 4 quarters. The position peaked at $548K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Aster Capital Management reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 182,089 ImmunityBio shares in Q2 2026, an estimated $548K.
  • Aster Capital Management first reported a position in ImmunityBio in Q4 2024 and held it in 4 quarters.
  • Aster Capital Management's ImmunityBio position peaked at $548K in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.